Disease · MONDO_0024332
Comparisons in its trials19
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 19 of 19
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Montelukast 10 mg vs Placebo: serious adverse events | 4 of 1,002 | 1 of 990 | 1,992 | NCT00092118 | Trial comparisons |
| Olopatadine 0.6% Nasal Spray vs Placebo Nasal Spray: serious adverse events | 15 of 445 | 15 of 445 | 890 | NCT00578331 | Trial comparisons |
| Ciclesonide Nasal Aerosol vs Ciclesonide Nasal Spray: Number of Subjects With Increase ≥ 7 mm Hg From Baseline in Intraocular Pressure, or a Change to > 21 mm Hg, in Either Eye | 9 of 367 | 6 of 370 | 737 | NCT01654536 | Trial comparisons |
| Ciclesonide Nasal Aerosol vs Ciclesonide Nasal Spray: Number of Subjects With Development of or Worsening in Lens Opacities. | 51 of 367 | 53 of 370 | 737 | NCT01654536 | Trial comparisons |
| Ciclesonide Nasal Aerosol vs Ciclesonide Nasal Spray: Number of Subjects With Change From Baseline in Best Corrected Visual Acuity. | 1 of 367 | 2 of 370 | 737 | NCT01654536 | Trial comparisons |
| Ciclesonide Nasal Aerosol vs Ciclesonide Nasal Spray: serious adverse events | 4 of 367 | 5 of 370 | 737 | NCT01654536 | Trial comparisons |
| Astepro 0.15% vs Nasonex®: serious adverse events | 4 of 466 | 4 of 237 | 703 | NCT00720382 | Trial comparisons |
| FF 110 mcg QD vs Placebo: serious adverse events | 12 of 367 | 7 of 181 | 548 | NCT00682643 | Trial comparisons |
| BDP Nasal Aerosol 80 mcg/Day vs Placebo Nasal Aerosol: serious adverse events | 0 of 362 | 0 of 185 | 547 | NCT01783548 | Trial comparisons |
| BDP HFA 320 µg/Day vs Placebo: serious adverse events | 8 of 415 | 3 of 111 | 526 | NCT00988247 | Trial comparisons |
| FFNS 110 mcg vs Placebo: serious adverse events | 2 of 237 | 4 of 237 | 474 | NCT00570492 | Trial comparisons |
| BDP HFA 320 µg/Day vs Placebo: serious adverse events | 1 of 236 | 0 of 238 | 474 | NCT01134705 | Trial comparisons |
| TAU-284 vs Placebo: serious adverse events | 0 of 240 | 0 of 232 | 472 | NCT01861522 | Trial comparisons |
| Fluticasone Furoate 110 mcg vs Placebo: serious adverse events | 0 of 160 | 0 of 155 | 315 | NCT00609674 | Trial comparisons |
| Fluticasone Furoate vs Placebo: deaths from any cause | 0 of 151 | 0 of 151 | 302 | NCT00289198 | Trial comparisons |
| Fluticasone Furoate vs Placebo: serious adverse events | 1 of 151 | 0 of 151 | 302 | NCT00289198 | Trial comparisons |
| BDP Nasal Aerosol 80 mcg/Day vs Placebo Nasal Aerosol: serious adverse events | 0 of 67 | 0 of 32 | 99 | NCT01697956 | Trial comparisons |
| Montelukast 4 mg OG/1-5 Year Olds vs Montelukast 5 mg CT/6-15 Year Olds: serious adverse events | 0 of 51 | 0 of 36 | 87 | NCT01852812 | Trial comparisons |
| Budesonide vs Placebo: serious adverse events | 0 of 20 | 0 of 20 | 40 | NCT01270256 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0024332/comparisons